H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Carisma Therapeutics to $8 from $9 and keeps a Buy rating on the shares post the Q1 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Securing Success: The Crucial Role of IP Rights in Carisma Therapeutics’ Market Dominance
- Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Carisma Therapeutics presents data for macrophages in liver fibrosis
- Carisma Therapeutics appoints Eugene Kennedy as Chief Medical Officer
- Carisma Therapeutics initiated with a Buy at BTIG